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Abstract 
The effect of withdrawal from chronic morphine or amphetamine treatment on dopaminc (DA) ncurotransmission in the 
ventral-medial striatum was studied by use of in vivo mierodialysis. There was no effect of 24 h of amphetamine withdrawal on 
the basal concentration of DA in the ventral-medial striatum. Spontaneous morphine withdrawal (24 h) was associated vdth a 
significant decrease in the basal concentration of DA in dialysatc, but tollowing morphine replacement and naloxonc-prccipi- 
tated withdrawal variations in withdrawal symptoms were not related to variations in the concentration of DA in dialysatc. It ix 
suggested that: (1) thc correlation between the cxtraccllular concentration of DA in the ventral-medial striatum and the 
symptoms of morphine withdrawal may not be indicative of a necessary', causal relationship; and (2) a decrease in the 
cxtraccllular concentration of DA in the ventral-medial striatum is not a common feature of drug withdrawal syndromes. 
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I. Introduction 
"l'hc withdrawal or abstinence syndrome associated 
with the discontinuation of chronic opiate drug use is 
quite different to that associated with the discontinua- 
tion of chronic psychomotor stimulant drug use. For 
example, the former includes a variety of overt neum- 
logic and vegetative signs, as well as subjective symp- 
toms of distress, whereas the latter is more subtle, 
consisting primarily of subjective symptoms [7]. How- 
ever, some of the subjective symptoms associated with 
opiate and psychomotor stimulant withdrawal are simi- 
lar, including anxiety, depression, dysphoria and drug 
craving. The similarity of the subjective symptoms of 
withdrawal across drug classes has led some investiga- 
tors to suggest they may have a common neurobiologi- 
cal substrate [2,16,18]. 
Mesotelencephalic dopamine (DA) systems arc 
known to play an important role in mediating the 
positive reinforcing effects of a variety of drugs of 
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abuse [21], and it has been suggested that an increase 
in DA ncurotransmission is responsible for the subjec- 
tive pleasurable aspects of drug action (see [14] for 
review and an alternative hypothesis). Given this vicw. 
it is reasonable to hypothesize that at decrease in DA 
neurotransmission may be responsible for some of the 
unpleasant subjective symptoms associated with drug 
withdrawal syndromes [2,16,18]. Consistent with this 
idea, a decrease in the extracellular concentration ol 
DA in the ventral striatum, as estimated by microdialy- 
sis, is reported to accompany the withdrawal syn- 
dromes associated with the abrupt discontinuation o t  
chronic treatment with ethanol [5,16,17]. morphine 
[I,2,13,16], amphetamine [16] or cocaine [6,1(),16,20]. 
Some researchers, on the other hand, have reported 
that amphetamine withdrawal is no t  accompanied by a 
decrease in the cxtracellular concentration of DA in 
the ventral striatum [4,19,22]. The purpose of the two 
experiments reported hcrc, therefore, was to re- 
evaluate the relationship between changes in cxtraccl- 
lular DA in the ventral-medial striatum, as estimated 
by in vivo microdialysis sampling, and the withdrawal 
syndromes associated with morphine vs. amphetamine 
abstinence. 
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2. Methods 
2.1. Experiment 1: Withdrawal from morphine 
Subjects 
Thirty male Sprague-Dawley rats, initially weighing 250-300 g, 
were housed individually in stainless steel hanging cages. The ani- 
mals had frec access to food and water and were maintained on a 
14:11) h l ight /dark  c3'cle. 
Surgery 
Each rat was anesthetized with sodium pentobarbital, and stand- 
ard stereotaxic techniques were used to place a 21 gauge thin-wall 
stainless steel guide cannula on the surface of the dura, above the 
ventral-medial striatum (nucleus accumbens; [12]). This was fixed in 
place with jeweler's screws and cranioplastic cement.  The rats were 
allowed to recover from surgery for at least 4 days before beginning 
drug treatments.  
Drug pretreatment and dialysis procedures 
The animals were given daily injections of morphine sulfate 
(Mallinckrodt) or 0.9% saline for 15 days according to a regimen 
adapted from Acquas et al. [1]. The animals were injected subcuta- 
neously twice per day (approximately 12 h apart) and the dose of 
morphine was escalated as follows: day 1, 10 m g / k g  (weight of the 
salt); day 2, 20 mg/kg ;  day 3-4,  40 mg/kg ;  day 5-6,  60 mg/kg ;  day 
7-8, 8(I mg /kg ;  day 9-10,  100 mg/kg ;  day 11-12, 120 mg/kg ;  day 
13-15, 140 mg/kg .  
On day 15 the animals were transferred from their home cages to 
the dialysis test chambers.  Approximately I h later they received one 
additional injection, and 2 h later each rat was briefly restrained 
manually while a dialysis probe (see below) was lowered into the 
ventral-medial striatum via the previously implanted guide cannula. 
The probes were perfused with a sterile salt solution containing 145 
mM NaCI, 2.7 mM KCI, 1.2 mM CaCI, ,  1.0 mM MgCI 2 and 0.2 mM 
ascorbic acid, pl l  7.3 [8], at a flow rate of  1.5 / z l /min  during probe 
implantation. The perfusion rate was then decreased to 0.3 /~l/min,  
and the animals were left undisturbed overnight in the test chamber.  
Approximately 22 h after the last injection of morphine or saline, 
the flow rate through the probes was increased to 1.5 p . l /min.  After 
a minimum stabilization period of 1 h, at least three 30-rain samples 
of dialysate were collected. After this, all of the morphine-pretreated 
(dependent)  rats were given an injection of 60 m g / k g  of morphine 
(s.c.), half of the saline-pretreated rats received 10 m g / k g  of mor- 
phine (s.c.), and the remaining saline-pretreated rats received 0.9% 
saline (s.c.). A dose of 60 m g / k g  of morphine was used in morphine- 
dependent  rats because in pilot studies we determined this was 
sufficient to alleviate withdrawal symptoms for over 2 h. Following 
the injection of morphine or saline three more 30-min samples of 
dialysate were collected. Next, all of the saline-pretreated rats were 
given an injection of 1 m g / k g  of naloxone (i.p.), half of the mor- 
phine-dependent  rats received 1 m g / k g  of naloxone (i.p.), and the 
remaining morphine-dependent  rats received no injection. Following 
this, four additional 30-min samples of dialysate were collected. 
Thus, there were four experimental groups: (1) morphine-dependent  
rats given morphine only; (2) morphine-dependent  rats given mor- 
phine followed by naloxone; (3) saline-pretreated rats given mor- 
phine followed by naloxone; and (4) saline-pretreated rats given 
saline fl)llowed by naloxone. 
the ventral-medial striatum. All probes were tested tor recovery of 
DA in vitro prior to use, and there were no group differences in 
recovery. The average recovery value for DA was 21.27+0.43%.. 
Dopamine in dialysate was separated by HPLC and analyzed using 
electrochemical detection, as described previously [15]. 
Behat,ior 
Behavior wes monitored continuously throughout the 5-h dialysis 
test session, and symptoms of withdrawal were scored using scales 
similar to those described by Blasig et al. [3]. Each incident of the 
following behaviors was scored as one point: teeth chattering, wet-dog 
shaking, jumping, and abdominal stretching. One continuous episode 
of teeth-chattering was scored as one point and duration was not 
recorded. In addition, the presence or absence of the following 
symptoms was recorded every 15 min, and one point was scored if 
the symptom was present: diarrhea, ptosis, lacrimation and vocaliza- 
tion upon a light touch to the back. The total "withdrawal score' for 
each animal was summed across 30-min intervals, corresponding to 
the 30-rain dialysis sample intervals. Thus, a high score on this scale 
I 
Dialysa probes 
Concentric dialysis probes similar to those described by Robinson 
and (;amp [15] were constructed from regenerated cellulose hollow 
dialysis fiber. One mm of stainless steel cannula and 7 mm of dialysis 
fiber extended below the skull surface. The dorsal 4 mm of fiber was 
coated with cyanoacrylate, leaving 3 mm of effective membrane  in 
Fig. 1. Schematic drawings of coronal sections of the rat brain 
adapted from the atlas of Paxinos and Watson [12]. The locations of 
the dialysis surface of probes used in Expt. 1 (morphine withdrawal) 
are illustrated on the left half of the sections, and the right half of 
the sections shows the location of probes used in Expt. 2 (ampheta-  
mine withdrawal). 
'q'; I )  ( r lpl~' lh,  1~1.. I{ol)FII~tnF BFUltF I¢Cs('IU( tl ( "~ J t /~,~()41 ~'h h. '  
reflects tile trequenl OCClFrrence ot the hcha,.it~rs and s~,.mpton~s 
s:.F nl pied. 
Follm~.ing the dialysis test session, cach animal  was given a lethal 
dose ol stadium pentoharbital, and then perfused through the heart 
v, ith (I.tJrl saliFlC and il l()'r.; l o rma lm solution. The brain was 
remuv~:d. Inlzcn and sectioned. The sections were stained with 
('resyl violet and examined to determine the exact probe placement. 
Only those animals with probes that had at least 75',; of the dialysis, 
surlae¢ within the ventral-medial striatum (primarily nucleus accum- 
bens) v.erc used m the cxperirnent. The neurochcmical data from 
lour animals were excluded d u e  tO incorrect prohe placenlents or 
b roken probes, hut the hehavioral  data h'om these animals were 
LFscd. 
2.2. I:.qwriment 2: Withdrawal fi'om amphetamine  
.S'uhject,~ and ~ur,w'rv 
Forty-three male Sprague-Dawle~, rats, initially weighiug 251) 3()U 
g. v, crc housed, and prepared with a guide cannula, as described in 
I{xpt. I. 
Drug treatment and  dialysis procedures 
"]'he rafts wcrc prctrcatcd with two injections per day. 9-12 h 
apart, of t~-amphctaminc sulfate (1.5 mg/kg,  i.p., weight of the salt) 
or 11.9'~ saline fi~r 14 consecutive days, as described by Rossetti et al. 
[16]. ()n day 15, the animals received only one injection of am- 
phetamine or saline in the morning. Approximately 2 h later, half of 
the amphetamine-pretreated and halt of the saline-pretreated ani- 
mals were given chloral hydrate (i.p.. 40{I mg/kg)  in three separate 
injections 1(1 m i n  apart  [16}. While these animals were anesthetized, 
a dialysis probe (sec above) was lowered into the ventral-medial 
qriatum via the previously implanted guide cannula, and the rats 
were then placed into the dialysis test chambers. The remaining rats 
were unl.~ briefly restrained (manualb') while the probe was lowered. 
During the implantation procedure the probes were perfused with 
the s,|mc sail solution as described in Expt. 1. at a flow rate of 1.5 
#l / ra in .  Following probe implantation the pump was turned off and 
the animals wcrc left undisturbed in the test chambers overnight. 
Approximately 23 h after the last injection of amphetamine or saline, 
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the petJH'q[H1 pump ",.vH,, IUllt~.,d till ;irF~.I lhc lh~\ ~, lal~.' ~.,,~i~ ~l'adLKlii', 
incleHsed tA~ I.~ /J] 111i11+ ..\II~_'l a 111illin~Hlli -,l;d',lli/,itl,,ii1 pcrltn.J ~q i 
h. al k.'a~,l fimr ~{M'nin sanff>IL':, ~l dial',sutc '.~.ul,.: ~tqh.'~.ted ~hflu the- 
animal,, '.~..crc other',~.i:,e umli,,tLHh....d 
Jhe dial~,~is ruolx..s ~,.cr~: :t,, descrihed ahmc. ,ud the .~u~ag~. ,n 
, . i tm reco'.er,. '.aim.' Its1 I t , \  ,aa,, lH .2 t ; - ( l .52  ' , \ i ] a l y l i ca l  ilil(.l hi,,h, 
logical pnx:eduru, ,  v, crc a', d~.',,cril~L'd f lu  l . ' , p l  I 
F i g  2. The mean ( - S . E . M . ) c o n c e n t r a t i o n  o l  dopamme ( D A ) m  
30-min dialysate samples ohta ined f rom tile vent ra l -med ia l  s t r iatum. 
p lo t ted  as a funct ion ol t ime. Values ".,'~erL' ,._'t'Jrreeted for l'~rcd~u 
reco,,ep,, determined in vitro (set' Section 2). Intervals BI I]3 repr~.'- 
sent has,,I values, intervals MI -M3  represent samples cullect~.'d 
fo l lowing morph ine  (or  :,aline) admin is t ra t ion,  and intcr,.als N I N.I 
represent samples collected following naloxone <~lr saline) admmi,,- 
tration. Triangles represent samples ohtaincd h'ln11 saline-pretreated 
rats and circles represent samples obtained from1 nlorphinc-pre- 
treated (dependent) rats. All salinc-pretrealed rats (n = 13l and all 
morphine-dependent rats { n -  13)',,.ere pooled to calculate the meal~ 
basal values (intc~.'als BI--B3). Following the collection ~1 three 
basal samples, the s~,line-pretreated group v, as divided into tv.o 
subgroups. The larger triangles represent those rats t ha l  reccixed Ill 
mg/kg morphine (n 8) and thc smaller triangles represent thos,: 
ruts that received saline (n = 5). Morphine <t~r salincl was gi'.en al 
the time indicated by the arrowhead labelled "M'. After morphine ~n 
saline administration, three additi,mal 3it-rain samples of dialysal~: 
were collected (inten,.als MI M3). After this. hoth subgroups ol 
saline-pretreated rats received 1.0 mg/kg  naloxonc, at the lime 
indicated by the arrowhead labelled "N'. and hmr additional sample, 
of dialysatc were collected. The Hack triangles represent, thercfuru. 
saline-pretreated rats t h a l  received morphine followed hy i la lox(m~:  
Following the collection of hasal samples, all of the morphine-dr: 
pendent rats received 60 rng/kg of morphine alld three 3[bmill 
samples were collected (c~pen circles, inter,,als M I.-M3). "['he tool 
phine-dependent group v.vs then divided into lV, t~ subgr,mlps. -]hu 
closed circles (inter',.als NI Nat represent morphine-dependent r:H,, 
that received l.II tng/'kg naloxc, nc ( n - 8 ) .  aFfd the open eirck.',, 
(intervals N I -N4) represen t  morphine-dependent rats that reccixcd 
no f u r t h e r  t r e a l n l e n l s  (,'i 5)..~'Fo'*~t.q~*~ ,'.,1+ ~ldl is t ical  +malx~ '~  I l l  
l 'he mean basal concentration o1 I)A was significantly Iov.ei in 
morphine-dependent rats than m saline-pretlealed raiN: comparison 
of the average of intervals BI-B3 for each gnmp. 1{24} t 3s. 
P-.  U.lRI24. (2) Morphine administration irlcreased D..\ in ]'vdh 
saline-pretreated (/-(.t,21 ) ~ 35.1. I' < (L(/0~H) and morphine-depend. 
enl groups (F(3.36). 433J7. P .  (I.Illllll: one.v, ay .,\NOVAs for t~.'- 
pealed measures, intervals B3-M3). (3) Saline administratiorl had n~ 
effect in saline-pretreated animals. ,,nd there was no change in [)..\ 
omcentrations throughout lh~ test session in Ihi>, group </-'(tL27) 
IL74, P = 0.67). (4) In morphine-dependent aninlals naloxone signili 
cantly decreased DA concentrations for the remainder ~1 the It.hi 
session (one-wa,,. ANOVA with repeated measures. /-'b.l.2S) ,',.5. 
f ~. [I.(IOUI. and follow-up I"isher's PLSD tests comparhlg inlcp,a[', 
M3 vs. N I-N4). (5) In saline-prctreated animal>, given morphim.'. 
naloxonc decreased I )A .  l~ut this was not statistical|', s ignif ieanl 
I~ased on a repeated me:.lSI.F1t.'s A N C ) V A  acr~lss int~.'r',,.als M3-N4 
(/-'(4,24)= 1.74. P -=1}.173 ): although there v,a,, a significant diflet- 
elite bet~ee[I inter',.al M3 a n d  the  average ot NI--N2 haxed on ;~ 
pah'ed l-tesl ( t (7 )  2.64. P : {L(1331. {e~l in morph inc -depeudem i,it', 
given naloxone. [)A concentrations ,.IM not differ Irtlm those in 
saline control animals (mean NI N4 samples in morphine-pry 
=1} . . . .  ::II.S2). and v,c,c treated rats vs. saline controls, t ( l l )  "~', I' 
higher than during spontarleoUS witlfdrawal ta'.'~:r,~ge ~1 N I N4 sam 
pies w,. average of BI.-B3 samples, paired l-lesl, l(7} 213. 1' 
{L(~53). 
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3. R e s u l t s  
3.1. Experiment 1." Withdrawal from morphine 
Histology 
Fig. 1 (left) illustrates the location of the dialysis 
probes in the ventral-medial striatum of animals used 
in this experiment. 
Dialysis 
Fig. 2 shows the mean (+  S.E.M.) concentration of 
DA in dialysate for each group during the entire dialy- 
sis test session. Fig. 2 shows that there was a significant 
decrease in the basal concentration of DA obtained 
from animals undergoing spontaneous withdrawal from 
morphine (intervals B1-B3). Indeed, the basal concen- 
tration of DA in morphine-dependent animals (0.43 + 
0.05 p g / g l )  was approximately half that in saline-pre- 
treated animals (0.81 + 0.10 pg/p.l; see the figure leg- 
ends for presentation of statistical analyses). 
In saline-prctreated animals, morphine administra- 
tion produced a significant increase in DA concentra- 
tions (intervals MI-M3) ,  which was reversed tran- 
siently by subsequent naloxone administration (inter- 
vals N I-N2).  Naloxone alone had no effect in control 
animals (Fig. 2). In morphine-dependent animals the 
administration of morphine also produced a significant 
increasc in DA concentrations (see Fig. 2), which was 
reversed by a naloxonc challenge (intervals N1-N4). It 
is important to note, however, that following the nalox- 
one challenge DA concentrations in morphine-depend- 
ent animals did not return to the depressed levels seen 
during spontaneous withdrawal, and in fact, during 
intervals N1-N4 DA concentrations in morphine-de- 
pendent animals did not differ significantly from those 
in saline control animals. 
Beharior 
Fig. 3 shows the average behavioral withdrawal rat- 
ings over the entire dialysis test session. Also, the 
average concentration of DA in dialysate is replotted 
from Fig. 1 for morphine-dependent animals given 
naloxone, and for saline control animals, to facilitate 
comparison of the behavioral and neurochcmical data. 
As expected, morphine-dependent animals exhibited 
spontaneous symptoms of withdrawal 1 day after their 
last pretreatment injection of morphine (intervals B1- 
B3; Fig. 3). Morphine administration eliminated the 
symptoms of withdrawal in morphine-dependent ani- 
mals (i.e., there were no group differences in with- 
drawal ratings during intervals M1-M3). Naloxone ad- 
ministration reinstated withdrawal symptoms in mor- 
phine-dependent animals, but had no effect on saline 
control animals (intervals N1-N2). Naloxone-precipi- 
tatcd withdrawal was maximal for about 1 h after 
naloxone administration, but by the second hour (inter- 
vals N3-N4)  withdrawal symptoms had dissipated. By 
the second hour after naloxone administration mor- 
phine-dependent animals did not differ from control, 
and also showed significantly fewer symptoms of with- 
drawal than at the beginning of the test session (i.e., 
intervals B I - B 3  vs. N3-N4). Morphine-dependent ani- 
mals given morphine followed by saline (instead of 
naioxone) did not show symptoms of withdrawal during 
intervals N l - N 4  (data not shown). 
A direct comparison of withdrawal symptoms and 
extracellular DA over the entire test session is espe- 
cially interesting (Fig. 3). Spontaneous withdrawal was 
associated with a decrease in the concentration of DA 
in dialysate, and the alleviation of withdrawal symp- 
toms by morphine replacement was associated with an 
increase in DA concentrations. Reinstatement of with- 
drawal symptoms by naloxone was accompanied by a 
decrease in DA concentrations. These results suggest a 
correlation between the concentration of DA in 
dialysate and the presence or absence of withdrawal 
symptoms. Fig. 3 also shows, however, clear dissocia- 
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Fig. 3. Each bar represents the mean ( + S.E.M.) rating of morphine 
withdrawal symptoms cumulated over 30-min intervals. The shaded 
bars represent ratings for morphine-pretreated (dependent) rats, and 
the open bars represent ratings for saline-pretreatcd rats. The closed 
circles represent the mean ( +_ S.E.M) DA concentrations in dialysatc 
for morphine-dependent rats given morphine followed by naloxone, 
and the open circles DA concentrations for the saline control group. 
The neurochemical data are replotted from Fig. 2 to facilitate 
comparison of the behavioral and neuroehemical data. Summary of 
the statistical analyses. (1) Morphine-dependent animals showed 
spontaneous symptoms of withdrawal (mean ratings over intervals 
B1-B3 for saline-pretreated vs. morphine-pretreated rats, Mann- 
Whitney U test, U= 0.0, P < 0.0001). (2)Morphine administration 
significantly reduced withdrawal symptoms in morphine-dependent 
rats (mean ratings for intervals BI-B3 vs. M1-M3, paired sign test, 
P < 0.0001), and for intervals MI-M3 morphine-dependent rats did 
not differ from control (Mann-Whitney U test). (3) Naloxone in- 
creased withdrawal symptoms in morphine-dependent rats for ap- 
proximately 1 h (ratings for intervals Ml-M3 vs. N1-N2, paired sign 
test, P = 0.002), but by the second hour after naloxone administra- 
tion symptoms of withdrawal dissipated (ratings for intervals M1-M3 
vs. N3-N4, paired sign test, P = 0.34). 
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tions between the concentration of I)A in dialysatc and 
the severity of withdrawal symptoms. First. although 
naloxonc administration prccipitated scverc with- 
drawal symptoms (intervals NI-N2) .  cxtraccllular I)A 
only decreased to levels seen in saline-pretreatcd rats. 
That is, during the first hour aftcr naloxone adminis- 
tration, when withdrawal symptoms were the most pro- 
nounced, the concentration of I)A in dialysatc ob- 
tained from morphine-dependent animals did not dif- 
fer from control, and was significantly higher than 
during spontaneous withdrawal (intcrvals B I-B3). See- 
end, in morphine-dependent animals the concentration 
of DA in dialysatc was constant ovcr thc 2 h following 
naloxone administration, but over this same period of 
time the symptoms of withdrawal ranged from their 
maximum (intervals N I -N2)  to near minimum (interval 
N4). 
3. 2. EMwriment 2: Withdrawal ]7"ore amphetamine 
Fig. 1 (right) illustrates the location of the dialysis 
probes in the ventral-medial striatum of animals used 
in this experiment. The mean basal concentrations of 
DA, DOPAC, HVA and 5-HIAA in dialysate for each 
group are given in Table 1. "l'herc was no effect of 
amphetamine withdrawal, or treatment with anesthesia 
24 h previously, on the concentrations of any of these 
compounds in dialysate, as determined by one-way 
analyses of variance: DA, F(3,30)= 0.799, P = 0.504: 
DOPAC, F(3,30) = 2.164, t '  = 0.113; HVA, F(3,30) = 
1.440, t ' =  0.251; 5-HIAA, F(3,30) = 0.199. I '=  0.896. 
4. Discussion 
Symptoms of spontaneous morphine withdrawal 
were clearly evident I day following discontinuation of 
chronic morphine treatment. Consistent with previous 
reports [I,2,16] (c.f. [13]). spontancous morphine with- 
drawal was associated with a ~ignilicam decrease in tlw 
c x t r a c e l l u i a r  eonccn t ra l Jon  o f  l ) i \  in Iht.' v c n l l a l  ,4t i i , i  
tun1, ;.is estimated by in rive mierodi;llysis. Morphine 
rephicemeni alleviated withdra~val ~,$.ml)iolns, ;lnd in- 
creased the extraccllular elmccnlralhul o1 I) i \. l'hcsc 
data are consistent wiih the hypothesi~ thai a deprt:,,- 
sion in extracelhilar DA may eontributc to some of the 
symptonls of nlorphJnt: w.ithdraw,il [2. lfl, 1~41. 
On the other hand, lhe cxpcrinwnt involving nalox- 
one-precipitated withdrawal shoves Ih;ii lhc synlplo111', 
of morphine withdrawal can be dissociated lrom the 
cxtracelluhtr concentration of DA. at lcasl in the ven- 
tral-medial strJatum, suggesting thai the correlation 
described above may not be Jndic;llivc of a direct 
causal rehitionship. Two examples of ;i dissociation 
between morphine withdrawal symptoms and cxtraccl- 
hihir I)A were found. First. although naloxonc admin- 
istration precipitated sc~erc withdra~al ',.~.mptoms, the 
dose of llaloxt)ne u s e d  hcrc on ly  dcelC~.lsed DA COll- 
centratJons lo control levels: not to the depressed 
levels seen during spontaneous w, ithdr,lwal. Second, 
the time course of naloxone-prccipitalcd withdrav~al 
symptoms was not correlated with changes in the con- 
ccntration of I)A in dialysate. Followhlg naloxonc ad- 
ministration, the withdrawal symptoms ,seen in mor- 
phine-dependent rats ranged from their maxinmm dur- 
ing thc first hour, to near minimum during thc hist 3(I 
min of the test session. Despitc tills marked ,<arialJon 
in withdrawal symptoms, lllerc was ml Ctlallgc in extra- 
celluhir I)A over thc same pcriod of timc. "l'hcsc disso- 
ciations between withdrawal synlptonls and tile concen- 
tration of DA in dialysatc suggest ll]at the symptoms of 
morphine withdrawal ca|mot be caused ,,olcly by varia- 
tion in the cxtraeelluhir eonccntrali(m ()I" I)t\  hi the 
vcntral-mcdial striatum. 
This conchisJon requ i res  a coup le  e l  ca\,¢ats. Fi rst .  
although our data suggest thai the sYml)loms of nlor- 
phine withdrawal cannel be attributed ~(lJl ' ]J'  [0 abnor- 
mally low extracellular eoneenirathms of [)A in the 
ventral-medial striatum, this does not nle{in that 
changes in striatal DA neurotransmission play no role 
in morphine withdrawal. The data onl,, establish that 
variation in the symptoms associated with morphine 
withdrawal cannot be explained b.~ \;.iriation in the 
extracellular concentration of DA ahmc. "l'hcrc may bc 
a variety of complex presynaptic and postsynaptic 
adaptations in I)A systems that occur during chronic 
exposure to morphine, and mteraction~ bctw.ecn vari- 
ous ncuroadaptations in DA systems mab. contribute to 
the morphine withdrawal syndrome. The nature of 
such putative interactions, and their relationship to thc 
morphine withdrawal syndromc, rcrnain to bc deter- 
mined. Second, the most obviou,', physical signs el 
withdrawal were quantified in the prcscnt Sltldy. not 
the avcrsivc subjective experiences tha i  s o n i c  re-  
searchers have proposed may be mcdiatcd by changes 
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in DA neurotransmission [2,16,18]. It is always possi- 
ble, therefore, that there was no dissociation between 
the subjectiL'e symptoms of withdrawal and extracellu- 
lar DA concentrations. This would require, however, 
that in this experiment subjective symptoms were ab- 
sent when the physical signs of withdrawal were maxi- 
mal. 
In contrast to the decrease in extracellular DA 
associated with spontaneous morphine withdrawal, 
there was no change in extracellular DA in the 
ventral-medial striatum during amphetamine with- 
drawal. This is consistent with a number of reports of 
no change in the basal extracellular concentration of 
DA in the nucleus accumbens over the first 5 days of 
amphetamine withdrawal [4,19,22]; but seems inconsis- 
tent with Rossetti et al. [16], who reported a significant 
decrease in extracellular DA in the ventral striatum for 
5 days following the discontinuation of chronic am- 
phetamine treatment. 
It is not clear what accounts for the discrepancy 
between the present study (and also [4,19,22]), and that 
of Rossetti et al. [16]. Our previous study of am- 
phetamine withdrawal [4], in which a quantitative ( 'no 
net flux') microdialysis method was used, differed from 
that of Rossetti et al. [16] in at least three potentially 
significant ways. First, in our previous study an escalat- 
ing dose amphetamine pretreatment regimen was used, 
in which each of six weekly cycles of five successive 
drug days were followed by two drug-free days. Thus, 
in this experiment animals experienced withdrawal sev- 
eral times prior to the dialysis test session ([22] as well), 
whereas, in the Rossetti et al. experiment [16] animals 
experienced withdrawal for the first time during the 
dialysis test session. This raises the possibility that the 
response to the first experience of amphetamine with- 
drawal may differ from subsequent experiences. In the 
present experiment, therefore, we used exactly the 
same pretreatment regimen as Rossetti et al. [16], thus 
eliminating this variable. Second, Rossetti et al. [16] 
reported the amphetamine withdrawal-associated de- 
crease in DA was maximal the first day following the 
discontinuation of amphetamine pretreatment, but in 
the other studies cited above animals were tested be- 
tween three and five days of withdrawal. Although 
symptoms of amphetamine withdrawal persist for up to 
7 days following the discontinuation of escalating dose 
amphetamine treatment [9,11], animals in the present 
study were examined on the first day of withdrawal to 
maximize the probability of detecting a withdrawal-re- 
latcd decreasc in DA concentrations. Third, in the 
Rossetti et al. [16] experiment animals received anes- 
thesia the day prior to the dialysis experiment, and in 
the other studies they did not. This raises the possibil- 
ity that the decrease in extracellular DA reported by 
Rossetti ct al. [16] was due to an interaction between 
residual effects of anesthesia and amphetamine with- 
drawal. To test this possibility in the present study, half 
the animals received anesthesia the day prior to the 
dialysis test session and half did not. Prior anesthesia 
had no effect on extracellular DA in the ventral-medial 
striatum. In conclusion, these three variables do not 
seem to account for the decrease in extracellular DA 
reported by Rossetti et al. [16]. 
Two other possibilities deserve mention. One, dif- 
ferent style microdialysis probes were used in different 
studies. Rossetti et al. [16] used transverse probes, and 
concentric vertical probes were used in the present 
experiment, and by others [4,19,22]. The implantation 
of a transverse probe requires a major surgical proce- 
dure the day before the dialysis test session. It is 
possible, therefore, that the decrease in DA observed 
by Rossetti et al. [16] was not due to amphetamine 
withdrawal alone, but to an interaction between the 
discomfort associated with recent surgical trauma and 
that associated with amphetamine withdrawal. A sec- 
ond possibility is that transverse probes sample a dif- 
ferent portion of the ventral striatum than the concen- 
tric probes used here and by others [4,19,22], and the 
effect of amphetamine withdrawal on extracellular DA 
is regionally spccific. Consistent with this hypothesis, 
we found recently that withdrawal from escalating dose 
amphetamine treatment is associated with a transient 
decrease in extracellular DA in the dorsolateral cau- 
date nucleus, but not the nucleus accumbens (P. Paul- 
son and T. Robinson, unpublished observations), sug- 
gesting there are indeed regional differences in the 
effects of amphetamine withdrawal on DA neurotrans- 
mission. 
In summary, under some experimental conditions 
there may be an association between the extracellular 
concentration of DA in the ventral striatum and am- 
phetamine or morphine withdrawal, but the data pre- 
sented here suggest this correlation probably is not due 
to a necessary, causal relationship. First, during mor- 
phine withdrawal it was possible to dissociate variation 
in the symptoms of withdrawal from variation in extra- 
cellular DA concentrations. Second, amphetamine 
withdrawal was not associated with any change in the 
concentration of extracellular DA in the ventral-medial 
striatum. Although the present study does not rule out 
the possibility that other, more complex, changes in 
DA neurotransmission play a role in drug withdrawal 
syndromes, it does suggest that a simple decrease in 
extracellular DA in the ventral-medial striatum is not a 
common feature of drug withdrawal syndromes, and 
does not play a simple causal role in producing thc 
symptoms of opiate withdrawal. 
Acknowledgements 
This research was supported by a grant from thc 
National Institute on Drug Abuse (04294). We thank 
t+" 1) ( ttl~l~+'tt~. I L t6d>msem I#am I¢+'~+'t+~+ h ¢ 51/+ ]<)+).ll 5n ¢,2 
I)iannc Camp and Kcith Trujillo for thcir helpful con> 
mcnts and advice, and Kaitlcn Browman, Hans ('rom- 
bag, Steve Simmcrvillc and Sonal Solanki t'or their 
assistance in conducting the experiments. 
References 
[11 Acquas, [!.. ( 'arboni, E. and Di Chiara. G., Profound depression 
of mesolimbic dopamine release after morphine withdrawal in 
dependent  rats. Eur. J. PharmacoL. 193 ( 1991 ) 133 134. 
[21 Acquas, E. and I)i ( 'hiara, G.. Depression of mcsolimbic 
dopamine transmission and sensitization to morphine during 
opiate abstinence. J. ,.\,'eurodwm.. 58 (1992) Ifi2fl-. 1625. 
[3] 131asig. J.. tterz, A.. Reinhold, K. ;rod Zieglgansbcrgcr, S.. 
Development of  physical dependence on morphine in respect to 
time and dosage anti quantification of the precipitated with- 
dr,t'~, al syndrome in rats. P, s3'chopharmacologia. 33 (1t)73) 19 • 38. 
[4] Crippcns. D., ( 'amp,  D.M. and Rohinson, T .L .  13asal extraccllu- 
lair dopaminc in the nucleus accumbens during amphetamine  
u, ithdrawal: a "no net f]ux' microdialysis stud.'., ,N'curo~tl. I,ctt.. 
IS4 (19t,~3) 145- 148 
151 Diana. M.. Pistis, M.. ( 'arboni. S.. (icssa. (;.1.. and Rossetti, 
Z.I .... Profound decrement of mcsolimbic doparninergic neu- 
ronal activity during cthanol withdrawal s.,,ndromc in rats: elcc- 
trophysioh~gical and biochemical cvidcncc. Proc. Nut/. Acad. SoL 
I",S',-I, t)() ( 19931 7966 7969. 
till Impcratt~. A.. Mele. A.. Scrocco, M.(;. arm Pt,glisi-Allegra, S., 
Chronic cocaine alters limbic extracellular dopamine. Neuro- 
chemical t',asJs for addiction, l:ur. J. Pharmacol.. 21" {ltt92) 
299 3()11. 
[7] Jallc. J.l | . ,  Drug addiction and drug abuse. I11 A.(.L Gilman. 
T.W. Rail. A.S. Nies and P. Taylor ([ds.) .  The Phurtr acologicul 
Bast.~ ot" "lTteralwuttc~. Peganmn Press. New York. lt)gll, pp. 
522 573. 
Is] Moghaddam. B. and Bunney, B.S.. hmic composition of micro- 
dial.vsis pcrfusing solution alters the pharmacologicM l'¢Spofl- 
si,,cncss and basal Otltflo~ of striata] dopanline. J. Neurochctn. 
53 (1989) 652 654. 
[9] Munn, E.M. and Wise. R.A., The clfects of escalalit~g doses of 
d-amphetamine ( A M P H ) o n  lateral hypothalamic intracranial 
scll-stJnmlation (ICSSI. Soc. Neurosci. Ah~tr.. 18 (D,u)2) 3fl4. 
[10J Parson.',. I..1t.. Smith. A.D. and Justice, J.B.. Jr.. Basal extracel- 
I t l lar dopamme is decreased m the rail nucleus accumbens 
during abstinence from chronic cocaine. Symqzw. 9 ( 1991 ) 6fl-b5. 
[11] Paulson, P.E.. ( 'amp,  D.IM. and Rohinson. T.li.. r h c  time 
'.'Otll'~,t2 O1 I I ; l l lMcn l  ] ' ,cha',Joral ,.Jcplc,,,.ioll dnd  IICl~lXlL'l l l bchm, 
IOI;11 '~,.:llsJlJ/LIt]Oll II1 I'C[illJtm Io rL'gJOIlil] h ld l l l  IIIO11~)iIIIli11£.' LO!I 
CCll tralJons t ] t l l i l l~  an lphc l ; i n lH lu  '~L, i thdla ' , ' ,a]  HI t~lt,,. />',x 
ctuqdmrmac+do~,,y, 1()3 I I tJt~l ) 4N) .l.t~_'. 
I I  21 t~axJn',~s, ( ;  i l l ld ~I~,'~I[M)II. ( ' .  / I l l ,  1~11 I~IIHII  i i i  ~' l l ' l+'¢Hllt l l  ( +,f,l'+ll 
I l l l l l 's ,  R;.t\.ell [>l~.'~,h. N,d~, ~. 'Y~lrk. 19Nh 
[131 f>t~lhu~,. I(.. Rada. P.  Mark.  (LP. and Ihwl+cl. IL( I . .  l)opan+mc 
Illi,.'l",v, lJ;ll)',j ', II1 th'..' tlt£t, lc'tl', HCCIIllIIlk'IP, th l lH l~  ,Idtl lC i l l ld chltHIl~. 
mt~rf~llinc, nu loxone-p lcc ip i la lcd ~,.ilhdrav, al amt chmidmc 
trc;.lt l l lell l. Hrz+ut t+c'x. 5e, h (19t i l l  34,R .35(I. 
[14] Rol+inson. "I'.t( and l'h.'lrldg+. K( '+.  l h c  m.ural ba,,i,, nl dlu.e 
Cra~,Jllg: i111 Hlcel|tJ',,,,.'-SCllSitJlalJon t l l¢or~ tfl ad,.IJctitm. Hral t t  
Re+ Rot.. 1~ (1993) 24" 291. 
115] Robinstm, 1.1-. and ( 'a l l lp+ DIM. .  l 'hc tCaslhilit.~ tel Iupcalvd 
n3icrodhdysis lor '~silhln-suhjccls design experiment,,:  MlldJ+,., ou 
the mesostr ialal  dopammc h.~st¢111, hi T. I+ Rnbinstm and . I B  
Just ice. . I  i. { [[d~. }. ~li(~,Mtalys~s in the \cur,~s( wn( c~. I(l',c', ic*. 
Amsterdam.  1991. pp. ]'-;9 234. 
[ lh ]  Rossetti. Z I . . .  t ln~,khm. ] .  end (icssa. ( i . I  .. Marked mhi lq tum 
Of 111t.'s~.llin11"~ic dop~lnlJllC rel,..',l~,t*: tl con l l l l t )n  I¢~11t11c o l  ~.'lhallol. 
m~H'phillC, coc~HllC and  , l l l lpl lcl~ln1[l lC ;iJ'~stJllClICC [11 i'il[%, f i l l  / 
Pharma, o/. 221 <19~2) 227 234. 
[17] Rt~ssetti. Z . I . .  Melts. 1.. (alh,.+lll..N+. l) ian:t.  M. and (iu,,sa. 
( L I  .. A lcoho l  ,.,,ith,.lrav,;d in rat,, is associatcd wi lh a marked tall 
ii1 cxtranet,  ronal dopaminc.  - Ih ohol ( 'hl l I:~1~ Roy. lh ( Iq92) 
52t) - 532. 
[18] Rossetti. Z.I.., Meli~,. t . .  ( 'arhuni.  S. and (ies~,a, (LI.., I)~amatit. 
dL'pleti,.~n of t11csolJnl[',Jc extracellular dopaminc all,2r u.ith 
drama[  l r on l  tTlorphJn¢+ a ]coho l  o r  cl.iCaJliC: il c1.1111t11()11 ItCtlr{)- 
chcnlical substrate for drug dcpendencc. In P.W. Kali,.as and 
It .1t.  Samson ( l-ds.L Ihc .\:eurohiolo~,.v ¢'I Drug aml .;Ih'oh,I 
.;hhhcmm. l 'he Nov, York  Academy nl Sciences. Nov, Yt~rk. 
1992. pp. 513 5lb. 
[19] Steal, I).S. and Kuczenski, R.. Ill ',ivo microdial'.sis rcxcals a 
dimini';hcd amphetanllne-induccd I)A ie~.ptillSC cortcsllondmg 
Io heha',Joral scnsJlizalhm prtlduccd by repealed anlphet;imJnc 
prclrcatnlenl.  Brain Rev. 571 ( 1992} 33fl- 33 "7. 
[20] Weis.',. F.. Markou. A.. I,orang. M.I'. and Kooh. (;.F.. Basal 
cxtracellular dopanamc Icxcls in tile nuclctlS ilt:ctlnll~cllS ;lit.' 
decreased during cocaine withdra',,,al allcl unlirmtcd-acccs', 
sell-administration, Brain Re.~.. 593 ( l t+It~ TM) 31-1 3 I,"; 
[21] Wise. R.A. and Boz:.trth, M A .  A psychumutur ,qinmhml fl~ct,y 
of ad,,lictJun, t'~sychoi. 16'~ . t)4 {It)871 4fit)--dt~2. 
[22] Wolf. M.[!., White, t..I.. Na~sar. R.. Ph~Mcrson.  R.,I. ;rod 
Khansa. M.R.. I)iflercntial development ol autorcceptor sul~- 
scn,,Jlhit', and etlhallced dopanlinc release dr.ring anlphclanlin,c 
scn,;itizalitm..I Pharmu< ol. I:'~l, Thor., 261 (1t,~93) 24~,~-255. 
